Immunogenicity of Pertussis Booster Vaccination in Children and Adolescents with Inflammatory Bowel Disease

Banaszkiewicz, Aleksandra; Gawrońska, Agnieszka; Klincewicz, Beata; Kofla-Dłubacz, Anna; Grzybowska-Chłebowczyk, Urszula; Toporowska-Kowalska, Ewa; Małecka, Ilona; Stryczyńska-Kazubska, Joanna; Feleszko, Wojciech; Łazowska-Przeorek, Izabella; Karolewska-Bochenek, Katarzyna; Walkowiak, Jarosław; J, Slusarczyk; Radzikowski, Andrzej; Demkow, Urszula; Albrecht, Piotr

doi:10.1097/mib.0000000000001076

Cited by 13 publications

(20 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies investigated multiple vaccines ( Table 1 ). The studies covered the non-live vaccines against Diphtheria Tetanus Polio (DTP, 6 studies), Hepatitis A virus (HAV, 4 studies), Hepatitis B virus (HBV, 7 studies), Human Papillomavirus (HPV, 4 studies), Influenza (13 studies), Meningococcus C (1 study) and Pneumococci (both the pneumococcal conjugate vaccination (PCV) and/or the 23-valent pneumococcal polysaccharide vaccine (PPSV-23) vaccine, 6 studies) ( 9 – 50 ). In addition, studies were included that reported on the live-attenuated vaccines against Measles, Mumps and Rubella (MMR, 12 studies, including 3 on the combined MMR-Varicella booster) ( 12 – 14 , 51 – 59 ), Varicella Zoster Virus (VZV, 5 studies) ( 59 – 63 ), one study which included 1 patient with oral polio vaccine ( 59 ) and one case report on the Bacillus Calmette-Guérin (BCG) vaccine ( 64 ).…”

Section: Resultsmentioning

confidence: 99%

“…Since the 2011 recommendations, six cohort studies including in total 650 pedAIIRD patients and 2219 healthy controls assessed the DTP (3 diphtheria, 1 pertussis, 4 tetanus) vaccination, with a maximum level of evidence of 2B for immunogenicity and safety (adverse events) ( 9 – 14 ). Efficacy was not evaluated; all studies assessed immunogenicity.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy, Immunogenicity and Safety of Vaccination in Pediatric Patients With Autoimmune Inflammatory Rheumatic Diseases (pedAIIRD): A Systematic Literature Review for the 2021 Update of the EULAR/PRES Recommendations

et al. 2022

View full text Add to dashboard Cite

BackgroundIn 2011, the first European League Against Rheumatism (EULAR) vaccination recommendations for pediatric patients with autoimmune inflammatory rheumatic diseases (pedAIIRD) were published. The past decade numerous new studies were performed to assess the safety, efficacy and immunogenicity of vaccinations in pedAIIRD. A systematic literature review (SLR) was therefore performed to serve as the basis for the updated 2021 EULAR/PRES recommendations.MethodsAn SLR was performed according to the standard operating procedures for EULAR-endorsed recommendations. Primary outcomes were efficacy, immunogenicity and safety of vaccination in pedAIIRD. The search was performed in Medline, Embase and the Cochrane Library and included studies published from November 2010 until July 2020.ResultsThe SLR yielded 57 studies which were included for critical appraisal and data extraction. Only 8 studies described the occurrence of vaccine-preventable infections after vaccination (efficacy), none of these studies were powered to assess efficacy. The majority of studies assessed (humoral) immune responses as surrogate endpoint for vaccine efficacy. Studies on non-live vaccines showed that these were safe and in general immunogenic. Biologic disease-modifying antirheumatic drugs (bDMARDs) in general did not significantly reduce seroprotection rates, except for B-cell depleting therapies which severely hampered humoral responses. Four new studies on human papilloma virus vaccination showed that this vaccine was safe and immunogenic in pedAIIRD. Regarding live-attenuated vaccinations, level 1 evidence of the measles mumps rubella (MMR) booster vaccination became available which showed the safety of this booster for patients treated with methotrexate. In addition, level 3 evidence became available that suggested that the MMR and varicella zoster virus (VZV) vaccination for patients on low dose glucocorticosteroids and bDMARDs might be safe as well.ConclusionsThe past decade, knowledge on the safety and immunogenicity of (live-attenuated) vaccines in pedAIIRD significantly increased. Data on efficacy (infection prevention) remains scarce. The results from this SLR are the basis for the updated EULAR/PRES vaccination recommendations in pedAIIRD.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Efficacy, Immunogenicity and Safety of Vaccination in Pediatric Patients With Autoimmune Inflammatory Rheumatic Diseases (pedAIIRD): A Systematic Literature Review for the 2021 Update of the EULAR/PRES Recommendations

et al. 2022

View full text Add to dashboard Cite

show abstract

“…An increased prevalence of rheumatoid arthritis has been reported in UC patients. Previous studies have also demonstrated that the pertussis vaccine was immunogenic and safe in pediatric patients with UC, particularly when used in combination with anti-TNF- α agents [ 27 , 28 ].…”

Section: Discussionmentioning

confidence: 99%

Identification of Differential Intestinal Mucosa Transcriptomic Biomarkers for Ulcerative Colitis by Bioinformatics Analysis

Cheng

Wang

et al. 2020

Disease Markers

View full text Add to dashboard Cite

Background. Ulcerative colitis (UC) is a complicated disease caused by the interaction between genetic and environmental factors that affect mucosal homeostasis and triggers inappropriate immune response. The purpose of the study was to identify significant biomarkers with potential therapeutic targets and the underlying mechanisms. Methods. The gene expression profiles of GSE48958, GSE73661, and GSE59071 are from the GEO database. Differentially expressed genes (DEGs) were screened by the GEO2R tool. Next, the Database for Annotation, Visualization and Integrated Discovery (DAVID) was applied to analyze gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. Then, protein-protein interaction (PPI) was visualized by Cytoscape with Search Tool for the Retrieval of Interacting Genes (STRING). Results. There were a total of 128 common DEGs genes, including 86 upregulated genes enriched in extracellular space, regulation of inflammatory response, chemokine-mediated signaling pathway, response to lipopolysaccharide, and cell proliferation, while 42 downregulated genes enriched in the integral component of the membrane, the integral component of the plasma membrane, apical plasma membrane, symporter activity, and chloride channel activity. The KEGG pathway analysis results demonstrated that DEGs were particularly enriched in cytokine-cytokine receptor interaction, TNF signaling pathway, chemokine signaling pathway, pertussis, and rheumatoid arthritis. 18 central modules of the PPI networks were selected with Cytotype MCODE. Furthermore, 18 genes were found to significantly enrich in the extracellular space, inflammatory response, chemokine-mediated signaling pathway, TNF signaling pathway, regulation of cell proliferation, and immune response via reanalysis of DAVID. Conclusion. The study identified DEGs, key target genes, functional pathways, and pathway analysis of UC, which may provide potential molecular targets and diagnostic biomarkers for UC.

show abstract

“…Most observational studies have shown no significant differences in immunogenic response between pediatric or adult patients with IBD irrespective of immunosuppressive therapy, or healthy controls ( 15 , 53 , 148–151 ). One study suggested that adults with IBD may have lower diphtheria and pertussis antibody concentrations compared to healthy subjects, with those on anti-TNF therapy having lower concentrations compared to those on thiopurine monotherapy ( 151 ).…”

Section: Inactivated Vaccines In Patients With Inflammatory Bowel Diseasementioning

confidence: 99%

Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 2: Inactivated Vaccines

Jones

Tse

Carroll

et al. 2021

Journal of the Canadian Association of Gastroenterology

View full text Add to dashboard Cite

Background and Aims The effectiveness and safety of vaccinations can be altered by immunosuppressive therapies, and perhaps by inflammatory bowel disease (IBD) itself. These recommendations developed by the Canadian Association of Gastroenterology and endorsed by the American Gastroenterological Association, aim to provide guidance on immunizations in adult and pediatric patients with IBD. This publication focused on inactivated vaccines. Methods Systematic reviews evaluating the efficacy, effectiveness, and safety of vaccines in patients with IBD, other immune-mediated inflammatory diseases, and the general population were performed. Critical outcomes included mortality, vaccine-preventable diseases, and serious adverse events. Immunogenicity was considered a surrogate outcome for vaccine efficacy. Certainty of evidence and strength of recommendations were rated according to the GRADE (Grading of Recommendation Assessment, Development, and Evaluation) approach. Key questions were developed through an iterative online platform, and voted on by a multidisciplinary group. Recommendations were formulated using the Evidence-to-Decision framework. Strong recommendation means that most patients should receive the recommended course of action, whereas a conditional recommendation means that different choices will be appropriate for different patients. Results Consensus was reached on 15 of 20 questions. Recommendations address the following vaccines: Haemophilus influenzae type b, recombinant zoster, hepatitis B, influenza, pneumococcus, meningococcus, tetanus-diphtheria-pertussis, and human papillomavirus. Most of the recommendations for patients with IBD are congruent with the current Centers for Disease Control and Prevention and Canada’s National Advisory Committee on Immunization recommendations for the general population, with the following exceptions. In patients with IBD, the panel suggested Haemophilus influenzae type b vaccine for patients older than 5 years of age, recombinant zoster vaccine for adults younger than 50 year of age, and hepatitis B vaccine for adults without a risk factor. Consensus was not reached, and recommendations were not made for 5 statements, due largely to lack of evidence, including double-dose hepatitis B vaccine, timing of influenza immunization in patients on biologics, pneumococcal and meningococcal vaccines in adult patients without risk factors, and human papillomavirus vaccine in patients aged 27–45 years. Conclusions Patients with IBD may be at increased risk of some vaccine-preventable diseases. Therefore, maintaining appropriate vaccination status in these patients is critical to optimize patient outcomes. In general, IBD is not a contraindication to the use of inactivated vaccines, but immunosuppressive therapy may reduce vaccine responses.

show abstract

Immunogenicity of Pertussis Booster Vaccination in Children and Adolescents with Inflammatory Bowel Disease

Abstract: Booster dose of pertussis vaccine was immunogenic and safe in pediatric patients with IBD.

Cited by 13 publications

References 24 publications

Efficacy, Immunogenicity and Safety of Vaccination in Pediatric Patients With Autoimmune Inflammatory Rheumatic Diseases (pedAIIRD): A Systematic Literature Review for the 2021 Update of the EULAR/PRES Recommendations

Efficacy, Immunogenicity and Safety of Vaccination in Pediatric Patients With Autoimmune Inflammatory Rheumatic Diseases (pedAIIRD): A Systematic Literature Review for the 2021 Update of the EULAR/PRES Recommendations

Identification of Differential Intestinal Mucosa Transcriptomic Biomarkers for Ulcerative Colitis by Bioinformatics Analysis

Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 2: Inactivated Vaccines

Contact Info

Product

Resources

About